IRD - Opus Bio P/S Multiple

Symbol and logo of brand Opus Bio (IRD)

The stable scientific climate in the US and the humanitarian status of Opus Genetics Inc (IRD) developments ensure predictable growth, as reflected in the current P/S ratio trend. The value 49.60 indicates the current level of this metric. Financial stability is based on strict ESG compliance and bioethics, while high market valuation is supported by unique delivery vector patents that create an insurmountable barrier for new entrants.

Opus Genetics, Inc. (IRD): Market Cap to Revenue from 10/25/2024 to 11/13/2026

Analytical breakdowns for Opus Genetics Inc (IRD)

- share price and expert price forecast:
Quote Chart opusgtx.com|IRD - Consensus Target
- market capitalization statistics:
Market Capitalization Opus Bio|IRD - Total Company Value
- balance sheet equity data:
Net Assets per Share Opus Genetics|IRD - Company Net Assets|Market Value to Book Value opusgtx.com|IRD - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Ratio Opus Genetics Inc|IRD - Long-Term Debt to Capital|Current Liabilities to Capital opusgtx.com|IRD - Company Debts|Debt to Book Value Ratio Opus Bio|IRD - Company Long-Term Debts|Short-Term Debt Opus Genetics|Intermediate Liquidity Ratio opusgtx.com
- net income and valuation ratios data:
IRD - Net Profit|Company Profit Forecast Opus Genetics Inc|IRD - P/E Multiple|Projected Price to Earnings opusgtx.com|IRD - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Opus Bio|IRD - Operating profit before deduction of amortization|Earnings per share for the trailing year Opus Genetics|IRD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months opusgtx.com|IRD - Earnings per share growth in current year|Projected earnings per share growth rate for next year Opus Genetics Inc
- sales revenue and business income indicators:
IRD - Revenue and Sales Volume|Company Future Sales Volume opusgtx.com|IRD - P/S Multiple|Market Cap to Expected Sales Ratio Opus Bio
Fundamental company analysis:Opus Genetics, Inc. (IRD)
Manufactured product of Opus Bio

Opus Genetics Inc (IRD) specializes in developing innovative gene therapy methods to combat hereditary blindness. The estimated price-to-sales ratio reflects the market value of the business relative to its actual sales. This multiple allows for an assessment of the premium paid for the future success of clinical trials and orphan drug status. It is critical for investors to benchmark this indicator against the commercialization rates of gene delivery technologies.

Competing companies

ALC: Price-to-Sales Ratio|Bausch + Lomb - Market Cap to Revenue|P/S Multiple Glaukos Corp GKOS|APLS - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Belite Bio, Inc BLTE|OCUL (Ocular Therapeutix) - Market Cap to Revenue|harrowinc.com - Market Capitalization-to-Revenue Ratio|VRDN (Viridian Therapeutics, Inc.) - P/S Multiple|LENZ - Price-to-Revenue Multiple|P/S Multiple OCS|EYPT - Price to Sales|Price-to-Revenue Ratio Kodiak Sciences Inc. KOD|ALDX: Market Cap to Revenue Ratio|Kala Pharmaceuticals - P/S Multiple|Price to Sales OKYO Pharma Limited|ADVM (adverum.com) - Market Cap to Revenue|OTLK: Market Cap to Sales Volume|CLSD (Clearside Biomedical) - P/S Multiple|NovaBay (NBY) - Price-to-Revenue Coefficient|P/S Multiple KPRX|Market Cap to Revenue alimerasciences.com ALIM|Price-to-Revenue Ratio Eyenovia EYEN|Price-to-Revenue Coefficient Guardion Health (GHSI)|OCUP: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio OPT (opthea.com)